loader2
Login Open ICICI 3-in-1 Account

Nifty Smallcap 50 Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Narayana Hrudayalaya Ltd. 17 Nov 2025 12:19 PM

Q2FY26 Quarterly Result Announced for Narayana Hrudayalaya Ltd.

Healthcare Facilities company Narayana Hrudayalaya announced Q2FY26 results

  • Consolidated total operating revenue was Rs 16,438 million for Q2FY26 as compared to Rs 13,667 million in the corresponding period of the previous year, reflecting a change of 20.3 % YoY and 9.1% QoQ.
  • Consolidated EBITDA stood at Rs 4,265 million, reflecting a margin of 25.9% as against Rs 3,323 million in Q2FY25, translating into a change of 28.3% YoY and 18.2% QoQ.
  • Consolidated PAT stood at Rs 2,583 million, reflecting a margin of 15.7% as compared to Rs 1,993 million in Q2FY25, translating into a change of 29.6% YoY and 31.7% QoQ.
  • India operating revenue was Rs 12,347 million for Q2FY26 as compared to Rs 11,351 million in the corresponding period of the previous year, reflecting a change of 8.8% YoY and 9.0% QoQ.
  • Cayman operating revenue was Rs 4,316 million for Q2FY26 as compared to Rs 2,423 million in the corresponding period of the previous year, reflecting a change of 78.1% YoY and 8.8% QoQ.

Emmanuel Rupert, Managing Director and Group CEO, Narayana Hrudayalaya, said: “The second quarter of the fiscal year has delivered a strong performance after a steady start to the year. We are pleased to report the highest-ever revenue and profitability at both India and the Group level. The performance improvement in India is attributable to strong growth in domestic footfall and improvements in payor mix, along with positive traction from our Clinics outreach, resulting in the highest ever profitability margins. Our hospital business in Cayman continues to deliver robust performance, with the Insurance business showing strong growth, resulting in record revenues for the region. We are confident that the synergies between the hospital and insurance businesses will deliver steady growth going forward in the Cayman region. The domestic Integrated Care business continues to be on a strong growth path, with our clinics garnering sizeable footfalls across all locations, providing a positive thrust to the overall business. After a steady start, our domestic Insurance business has shown strong momentum this quarter and we expect to build on this further going forward. We will continue to invest in this business and are optimistic that it will be a significant driver of growth to the NH ecosystem. We thank the investor community for their faith in us and remain confident of delivering on expectations for the year.”

Result PDF

Pharmaceuticals company Natco Pharma announced Q2FY26 results

  • Consolidated total revenue of Rs 1,463.0 crore for Q2FY26 as against Rs 1,434.9 crore as of 30th September 2024.
  • EBITDA (including other income) for the quarter was at Rs 679.2 crore with margins at 46.4%.
  • The net profit for the period, on a consolidated basis was Rs 517.9 crore.
  • The Board of Directors have declared an interim dividend of Rs 1.5 per equity share of Rs 2 each during Q2FY26.

Result PDF

Consumer Electronics company PG Electroplast announced Q2FY26 results

  • Revenues stood at Rs 655.37 crore, down 2.4% YoY.
  • EBITDA stood at Rs 44.68 crore vs Rs 60.54 crore in Q2FY25 – down 26.2%.
  • Net Profit for the quarter stood at Rs 2.38 crore, vs Rs 19.47 crore in Q2FY25.

Vikas Gupta, Managing Director, said: “Sales performance in the first half of FY26 was impacted by subdued demand in the Room AC segment, resulting in a moderated growth. However, underlying demand indicators remain healthy, and the recent reduction in GST rates is expected to enhance product affordability and accelerate category penetration over the medium term. Given the structurally low penetration of Room ACs in India, we continue to see significant headroom for sustained growth.

Capital efficiency continues to be a key operating principle, with all capital allocation decisions guided by sustainable profitability and value-accretive metrics. While near-term growth momentum may moderate, the medium to long-term outlook remains positive. The Company is committed to building a resilient, high-performing organization that consistently delivers superior returns and long-term stakeholder value.

The Company remains steadfast in its focus on research and development, product innovation, capital-efficient expansion, and strengthening strategic client partnerships. Ongoing investments in new platform development and capacity augmentation across core product categories are progressing as planned.”

Result PDF

Electric Utilities company Reliance Power announced Q2FY26 results

  • Q2FY26 Total income Rs 2,067 crore (USD 239 million) vs Q2FY25 Total income Rs 1,963 crore (USD 227 million).
  • Q2FY26 EBITDA Rs 618 crore (USD 72 million) vs Q2FY25 EBITDA Rs 376 crore (USD 44 million) ~ YoY increase of 64%.
  • Q2FY26 PAT Rs 87 crore (USD 10 million) vs Q2FY25 loss Rs -352 crore (USD -41 million) ~ YoY increase of 125%.
  • Debt to equity ratio at 0.87, among the lowest in the industry.
  • Debt servicing of Rs 634 crore (USD 73 million) IN Q2FY26 – reflecting continued commitment to debt reduction..
  • Q2FY26 Networth Rs 16,516 crore (USD 1,860 million).

Result PDF

Heavy Electrical Equipment company KEC International announced Q2FY26 results

  • Revenue: Rs 6,092 crore against Rs 5,113 crore.
  • EBITDA: Rs 430 crore against Rs 320 crore.
  • EBITDA Margin: 7.1% against 6.3%.
  • Interest as % to Revenue: 2.8% against 3.3%.
  • PBT: Rs 213 crore against Rs 113 crore.
  • PBT Margin: 3.5% against 2.2%.
  • PAT: Rs 161 crore against Rs 85 crore.
  • PAT Margin: 2.6% against 1.7%.
  • Order Intake: YTD Order intake of Rs 16,050 crore, healthy growth of ~20% YoY.
  • Order Book: YTD Order Book of Rs 39,325 crore; Additionally, L1 of ~Rs 5,000 crore.
  • Net Debt including Acceptances stands at Rs 6,480 crore as on 30 Sept’25 vis-a-vis Rs 5,265 crore as on 30 Sept’24.
  • Net Working Capital (NWC) stands at 138 days as on 30 Sept’25 vis-a-vis 130 days as on 30 Sept’24.

Vimal Kejriwal, MD & CEO, KEC International, said: “We have delivered another quarter of strong performance, marked by robust revenue growth, significant improvement in profitability and healthy order intake. Our EBITDA margins have continued their upward trajectory, expanding by 80 bps to 7.1% in Q2FY26, compared to 6.3% in the same quarter last year. The bottom line has also seen exceptional growth, with PBT and PAT rising by 88% YoY. The order book has been substantially strengthened with multiple strategic wins, taking the combined order book and L1 position to a record level of over Rs 44,000 crore. With a strong focus on execution, robust order book and a substantial tender pipeline, we are well positioned to drive sustained and profitable growth in the coming quarters.”

Result PDF

Pharmaceuticals company Neuland Laboratories announced Q2FY26 results

  • Total Income: Rs 516.1 crore compared to Rs 315.2 crore during Q2FY25, change 63.70%.
  • EBITDA: Rs 156.9 crore compared to Rs 65.7 crore during Q2FY25, change 138.80%.
  • EBITDA Margin: 30.40% for Q2FY26.
  • PBT: Rs 129.0 crore compared to Rs 48.5 crore during Q2FY25, change 166.60%.
  • PAT: Rs 96.5 crore compared to Rs 32.0 crore during Q2FY25, change 201.60%.

Sucheth Davuluri, Vice-Chairman & Chief Executive Officer, said: “The record high revenue this quarter driven by CMS commercial projects led to the operating leverage reflected in the EBITDA margins, and we expect this momentum to continue through the rest of the year. Given the investments we are making Neuland is well positioned to take advantage of the number of growth opportunities available to us in both the CDMO as well as the generic APIs space.”

Saharsh Davuluri, Vice Chairman & Managing Director, Neuland Laboratories, said: “Customer interest in Neuland’s capabilities continues to be on the rise as we see increased engagement with a diverse range of customers. Our reputation and track record as an agile partner is enabling not just new business but for greater share of business from existing customers. Our investments are going according to plan and helping to further differentiate Neuland as a partner of choice.”

Result PDF

Holding Companies company Cholamandalam Financial Holdings announced Q2FY26 results

Consolidated Financial Highlights:

  • Consolidated total income for Q2FY26 is Rs 9,589 crore as against Rs 8,180 crore in Q2FY25, registering a growth of 17%.
  • For Q2FY26, the Company has achieved consolidated PAT of Rs 1,214 crore as against Rs 1,125 crore in Q2FY25, registering a growth of 8%.

Standalone Financial Highlights: 

  • The total income of the company for Q2FY26 is Rs 30.07 crore as against Rs 29.13 crore in Q2FY25.
  • PAT for Q2FY26 is Rs 27.16 crore as against Rs 23.52 crore in Q2FY25.

Result PDF

Healthcare Facilities company Aster DM Healthcare announced Q2FY26 results

  • Revenue for Q2FY26 grew 10% YoY and 11% QoQ to Rs 1,197 crore.
  • Operating EBITDA grew 13% YoY and 22% QoQ to Rs 263 crore. in Q2FY26.
  • Operating EBITDA Margins stood at 22.0% in Q2FY26 vs 21.4% in Q2FY25 and 20.0% in Q1FY26.
  • Normalised PAT (Post NCI) grew 14% YoY and 23% QoQ to Rs 110 crore. In Q2FY26.

Azad Moopen, Founder & Chairman, Aster DM Healthcare, said: “Aster DM Healthcare delivered a steady performance in Q2FY26, with revenue increasing 10% yearon-year to Rs 1,197 crore despite lower incidence of seasonal illness. Adjusting for thistemporary seasonal effect, the company’s underlying revenue growth stood at 13%, demonstrating the strength of its core business operations. Operating EBITDA grew by 13% YoY and 22% QoQ during the quarter, reflecting stronger cost efficiency and operating leverage across the network.

The Kerala cluster demonstrated a strong turnaround in FY26, emerging from last year’s softness with renewed momentum and discipline. Following decisive leadership strengthening, operational tightening, and the revival of MVT partnerships, performance rebounded sharply. In Q2FY26, Kerala delivered its highest-ever quarterly revenue of Rs 620 crore with QoQ growth of 12%, driven by inpatient volumes growing by 13% QoQ and MVT revenue surging 67% QoQ. This momentum will further be supported with the recently operationalized 264-bedded Aster Kasaragod, strengthening our presence in northern Kerala.

We have made progress on the merger with Quality Care India Ltd. with stock exchange no-objection letters now received. The combined platform will create one of India’s most integrated and scalable healthcare networks, with complementary cluster strengths and enhanced clinical depth. Together with ongoing investments in digital health and efficiency-focused operating improvements, Aster remains well-positioned to deliver sustainable, long-term growth across its key markets.”

Result PDF

Capital Markets company Multi Commodity Exchange of India announced Q2FY26 results

  • Revenue from Operations Rs 374.23 crore, registering a growth of ~ 31% over Q2FY25.
  • EBITDA increased to Rs 270.19 crore, ~32% YoY growth.
  • Profit After Tax (PAT) Rs 197.47 crore, ~29% YoY growth.
  • Average Daily Turnover (ADT) increased to Rs 411,270 crore, reflecting the trust of our stakeholders and market participants alike.

Praveena Rai, Managing Director & CEO, MCX, said: “It gives me great pleasure to share our results of resilient performance. Our continued growth across product segments and strong participation reflect the confidence that market participants have in MCX’s transparent market ecosystem.

We remain committed to expanding our product offerings and deepening market penetration, further strengthening our role as the preferred destination for commodity derivatives trading in India.

MCX continues to strengthen its leadership in India’s commodity derivatives market by enhancing technology infrastructure, deepening market participation, and introducing innovative products that cater to the evolving needs of stakeholders”.

Result PDF

Specialty Chemicals company Aarti Industries announced Q2FY26 results

  • Revenue: Rs 2,250 crore, up 21% QoQ, led by improved volumes across key product categories.
  • EBITDA: Rs 292 crore, up 36% QoQ, reflecting higher capacity utilisation and cost optimisation.
  • PAT: Rs 105 crore, up 150 % QoQ, driven by better operating leverage and after considering exceptional items (as detailed in the financials declared earlier).
  • CAPEX: Rs 267 crore for the quarter; FY26 outlay expected below Rs 1,000 crore, reflecting continued capital discipline.

Suyog Kotecha, Executive Director & Chief Executive Officer, said: “This quarter reflected the inherent resilience and agility of our diversified portfolio. Despite US tariff headwinds, our strong customer engagement and proactive regional rebalancing helped us maintain the momentum. We are expanding our footprint in Europe, the Middle East, and Africa while optimising our US strategy to ensure long-term competitiveness. With key capacity additions nearing completion, Aarti Industries is well-positioned to capitalise on the next phase of global recovery. Our focus remains clear: to de-risk operations, accelerate innovation in high-growth chemistries, and maintain strong financial discipline. As trade flows stabilise and demand revives, we anticipate steady margin expansion across our portfolio."

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Play Store App Store
market app